ARTICLE | Clinical News

argenx rises on ARGX-113, ARGX-110 readout

December 12, 2017 12:25 AM UTC

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) jumped $24.02 (79%) to $54.47 on NASDAQ Monday after reporting data on its two lead compounds, efgartigimod (ARGX-113) and ARGX-110. The biotech gained €14.20 (56%) to €39.40 on Euronext.

Of 24 myasthenia gravis patients in a Phase II study, 75% of patients treated with efgartigimod achieved at least a 2 point reduction from baseline in the Myasthenia Gravis Activity-of-Daily-Living (MG-ADL) score vs. 25% of placebo-treated patients (p=0.0391). Efgartigimod was well tolerated with no serious or severe adverse events reported. The trial enrolled patients with confirmed generalized muscle weakness and an MG-ADL score of at least five with more than 50% of the score consisting of non-ocular items. Patients received standard of care (SOC) plus once-weekly 10 mg/kg efgartigimod for four weeks or placebo...

BCIQ Company Profiles

argenx S.E.